$KPTI
Karyopharm Therapeutics Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023036780 Filed on August 02, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $36.01M $37.58M
YoY Change -0.38% -5.29%
Cost Of Revenue $900.0K $1.194M
YoY Change -8.16% 27.16%
Gross Profit $35.10M $36.39M
YoY Change -0.18% -6.08%
Gross Profit Margin 97.48% 96.82%
Selling, General & Admin $30.81M $34.48M
YoY Change -11.08% -7.65%
% of Gross Profit 87.76% 94.77%
Research & Development $35.55M $31.48M
YoY Change 13.37% -28.96%
% of Gross Profit 101.29% 86.51%
Depreciation & Amortization $80.00K $83.00K
YoY Change -56.04% -44.3%
% of Gross Profit 0.23% 0.23%
Operating Expenses $67.27M $65.96M
YoY Change 1.92% -20.14%
Operating Profit -$31.26M -$29.57M
YoY Change 1.37% -31.08%
Interest Expense $6.073M -$2.960M
YoY Change -211.31% -146.89%
% of Operating Profit
Other Income/Expense, Net -$3.234M $30.00K
YoY Change -20312.5% -100.5%
Pretax Income -$34.49M -$32.50M
YoY Change -4.92% -33.59%
Income Tax $12.00K $127.0K
% Of Pretax Income
Net Earnings -$34.51M -$32.63M
YoY Change -5.0% -33.49%
Net Earnings / Revenue -95.83% -86.83%
Basic Earnings Per Share -$0.30 -$0.29
Diluted Earnings Per Share -$0.30 -$0.29
COMMON SHARES
Basic Shares Outstanding 114.4M 114.0M
Diluted Shares Outstanding 114.4M 114.2M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $208.3M $236.8M
YoY Change 40.39% 38.58%
Cash & Equivalents $43.66M $80.89M
Short-Term Investments $164.7M $155.9M
Other Short-Term Assets $13.80M $18.66M
YoY Change -67.61% -41.82%
Inventory $3.105M $3.672M
Prepaid Expenses
Receivables $37.90M $32.28M
Other Receivables $0.00 $0.00
Total Short-Term Assets $263.2M $291.4M
YoY Change 18.21% 20.18%
LONG-TERM ASSETS
Property, Plant & Equipment $686.0K $6.062M
YoY Change -91.35% 334.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M $387.0K
YoY Change 107.67% -93.0%
Total Long-Term Assets $6.738M $6.449M
YoY Change -21.28% -54.04%
TOTAL ASSETS
Total Short-Term Assets $263.2M $291.4M
Total Long-Term Assets $6.738M $6.449M
Total Assets $270.0M $297.8M
YoY Change 16.75% 16.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $943.0K $2.287M
YoY Change 15.99% 35.01%
Accrued Expenses $55.71M $54.89M
YoY Change -4.74% -2.62%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $62.08M $58.93M
YoY Change 0.51% -5.78%
LONG-TERM LIABILITIES
Long-Term Debt $303.2M $303.2M
YoY Change 0.1% 0.17%
Other Long-Term Liabilities $1.428M $6.935M
YoY Change -79.19% -8.56%
Total Long-Term Liabilities $1.428M $310.2M
YoY Change -99.54% -0.04%
TOTAL LIABILITIES
Total Short-Term Liabilities $62.08M $58.93M
Total Long-Term Liabilities $1.428M $310.2M
Total Liabilities $370.4M $369.1M
YoY Change -0.31% -1.0%
SHAREHOLDERS EQUITY
Retained Earnings -$1.445B -$1.411B
YoY Change 11.16%
Common Stock $1.346B $1.340B
YoY Change 16.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$100.4M -$71.25M
YoY Change
Total Liabilities & Shareholders Equity $270.0M $297.8M
YoY Change 16.75% 16.12%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$34.51M -$32.63M
YoY Change -5.0% -33.49%
Depreciation, Depletion And Amortization $80.00K $83.00K
YoY Change -56.04% -44.3%
Cash From Operating Activities -$29.53M -$25.70M
YoY Change 4.09% -26.88%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$7.680M $21.17M
YoY Change -165.57% -157.85%
Cash From Investing Activities -$7.680M $21.17M
YoY Change -165.79% -157.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 860.0K
YoY Change -100.0% -34.5%
NET CHANGE
Cash From Operating Activities -29.53M -25.70M
Cash From Investing Activities -7.680M 21.17M
Cash From Financing Activities 0.000 860.0K
Net Change In Cash -37.21M -3.668M
YoY Change 241.44% -94.79%
FREE CASH FLOW
Cash From Operating Activities -$29.53M -$25.70M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$29.53M -$25.70M
YoY Change 4.23% -26.88%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001503802
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36167
dei Entity Registrant Name
EntityRegistrantName
Karyopharm Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3931704
dei Entity Address Address Line1
EntityAddressAddressLine1
85 Wells Avenue, 2nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Newton
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02459
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
658-0600
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
KPTI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
114354540
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80894000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
135188000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
155871000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
142779000
CY2023Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
32280000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
47086000
CY2023Q2 us-gaap Inventory Net
InventoryNet
3672000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
114340000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4224000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
18097000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
19821000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
567000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1064000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
291381000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
350162000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
766000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1139000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5296000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6238000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
387000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
633000
CY2023Q2 us-gaap Assets
Assets
297830000
CY2022Q4 us-gaap Assets
Assets
358172000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2287000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2773000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
51808000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
58415000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3084000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2872000
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1749000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1848000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
58928000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
65908000
CY2023Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
170497000
CY2022Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
170105000
CY2023Q2 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132718000
CY2022Q4 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132718000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4500000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
6097000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2435000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2023Q2 us-gaap Liabilities
Liabilities
369078000
CY2022Q4 us-gaap Liabilities
Liabilities
374828000
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
114340000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
113213000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
113213000
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
12000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1340218000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1327909000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-783000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-638000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1410695000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1343939000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-71248000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-16656000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
297830000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
358172000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
37579000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39679000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
76277000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
87349000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31477000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44309000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
63816000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86371000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
34481000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37339000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
70388000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
76107000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
67152000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
82587000
us-gaap Operating Expenses
OperatingExpenses
136749000
us-gaap Operating Expenses
OperatingExpenses
164843000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-29573000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-42908000
us-gaap Operating Income Loss
OperatingIncomeLoss
-60472000
us-gaap Operating Income Loss
OperatingIncomeLoss
-77494000
CY2023Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
2824000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
293000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5673000
us-gaap Investment Income Interest
InvestmentIncomeInterest
367000
CY2023Q2 us-gaap Interest Expense
InterestExpense
5784000
CY2022Q2 us-gaap Interest Expense
InterestExpense
6313000
us-gaap Interest Expense
InterestExpense
11542000
us-gaap Interest Expense
InterestExpense
12997000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-234000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-86000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2930000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6033000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6103000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12716000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-32503000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48941000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66575000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-90210000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
127000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
121000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
181000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
251000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-32630000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-49062000
us-gaap Net Income Loss
NetIncomeLoss
-66756000
us-gaap Net Income Loss
NetIncomeLoss
-90461000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.59
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.15
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114207000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
114207000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79651000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79651000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113846000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113846000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78616000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78616000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-32630000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-49062000
us-gaap Net Income Loss
NetIncomeLoss
-66756000
us-gaap Net Income Loss
NetIncomeLoss
-90461000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-297000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-170000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-264000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-184000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-67000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-455000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
119000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-545000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32994000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49687000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66901000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-91190000
us-gaap Profit Loss
ProfitLoss
-66756000
us-gaap Profit Loss
ProfitLoss
-90461000
us-gaap Share Based Compensation
ShareBasedCompensation
11449000
us-gaap Share Based Compensation
ShareBasedCompensation
22429000
us-gaap Depreciation
Depreciation
373000
us-gaap Depreciation
Depreciation
326000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
392000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
400000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
2141000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
71000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-3000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
4000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-14806000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
982000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-552000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-636000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1724000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
14860000
kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-942000
kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-808000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-486000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
91000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4081000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-11567000
kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1385000
kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1086000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44608000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-94341000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
79000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
85308000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
48468000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
96526000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
99020000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11218000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50631000
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
0
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
29294000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
860000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2802000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
860000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32096000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-71000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-544000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-55037000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-113420000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
136885000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
197445000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81848000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84025000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80894000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82248000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
567000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1146000
CY2023Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
387000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
631000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
81848000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84025000
us-gaap Interest Paid Net
InterestPaidNet
2588000
us-gaap Interest Paid Net
InterestPaidNet
2588000
kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
1847000
kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
1682000
us-gaap Payments For Royalties
PaymentsForRoyalties
8192000
us-gaap Payments For Royalties
PaymentsForRoyalties
20746000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-45174000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
860000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6060000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-297000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-67000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-32630000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-71248000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-83079000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1335000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15093000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-170000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-455000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-49062000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-116338000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-16656000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
860000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11449000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-264000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
119000
us-gaap Net Income Loss
NetIncomeLoss
-66756000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-71248000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-79673000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2802000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22429000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29294000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-184000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-545000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-116338000
kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
19529000
kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
30039000
CY2023Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
227418000
CY2023Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
2800000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
265906000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1124000
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1370000
CY2023Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
1700000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1878000
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
848000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
976000
CY2023Q2 us-gaap Inventory Net
InventoryNet
3672000
CY2022Q4 us-gaap Inventory Net
InventoryNet
4224000
CY2023Q2 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
9119000
CY2022Q2 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
10669000
CY2022Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
2800000
CY2023Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
156481000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
1000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
611000
CY2023Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
155871000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
143123000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
4000
CY2022 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
348000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
142779000
CY2023Q2 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2023Q2 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
69
CY2022Q4 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
60
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
146814000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
580000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
3361000
CY2023Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
31000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
150175000
CY2023Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
611000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
129131000
CY2022Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
348000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
129131000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
348000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6060000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15093000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11449000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22429000
kpti Debt Instrument Convertible Threshold Measurement Period Description
DebtInstrumentConvertibleThresholdMeasurementPeriodDescription
during the five-business day period immediately after any five consecutive trading day period
us-gaap Debt Instrument Convertible Threshold Consecutive Trading Days1
DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
5
kpti Principal Amount Of Notes Used In Conversion Rate
PrincipalAmountOfNotesUsedInConversionRate
1000
kpti Debt Instrument Convertible Threshold Maximum Percentage Of Product Of Last Reported Sale Price Of Common Stock
DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock
0.98
ecd Trd Arr Ind Name
TrdArrIndName
Barry Greene
ecd Trd Arr Ind Title
TrdArrIndTitle
lead independent director
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
true
CY2023Q2 ecd Trd Arr Securities Agg Avail Amt
TrdArrSecuritiesAggAvailAmt
3030000
ecd Trd Arr Adoption Date
TrdArrAdoptionDate
September 30, 2023
CY2023Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2023Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-23-036780-index-headers.html Edgar Link pending
0000950170-23-036780-index.html Edgar Link pending
0000950170-23-036780.txt Edgar Link pending
0000950170-23-036780-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
kpti-20230630.htm Edgar Link pending
kpti-20230630.xsd Edgar Link pending
kpti-ex10_4.htm Edgar Link pending
kpti-ex10_5.htm Edgar Link pending
kpti-ex31_1.htm Edgar Link pending
kpti-ex31_2.htm Edgar Link pending
kpti-ex32_1.htm Edgar Link pending
kpti-ex32_2.htm Edgar Link pending
kpti-ex3_1.htm Edgar Link pending
kpti-ex4_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
kpti-20230630_cal.xml Edgar Link unprocessable
kpti-20230630_lab.xml Edgar Link unprocessable
kpti-20230630_pre.xml Edgar Link unprocessable
kpti-20230630_htm.xml Edgar Link completed
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
kpti-20230630_def.xml Edgar Link unprocessable